Enterprise of Rosatom State Corporation
Print version

Industry news

ROSATOM helps Kyrgyzstan develop nuclear medicine

An expert commission of representatives of the Ministry of Health of the Kyrgyz Republic and ROSATOM completed the key stage of the roadmap for the project to create a new department of radionuclide diagnostics for the treatment of patients with oncological and other socially significant diseases at the National Center for Oncology and Hematology (NCОН) in Bishkek.

ROSATOM took part in the 66th IAEA General Conference

ROSATOM took part in the 66th annual session of the General Conference of the International Atomic Energy Agency (IAEA) which was held in Vienna on September, 26-30, 2022. In total 175 IAEA member countries were represented at the Conference in this year.

ANSTO National Medical Facility to Triple Production of Radiopharmaceuticals

ANM project at ANSTO will benefit the Australian health industry and position Australia as a global leader in the high-end manufacturing of nuclear medicine.

Areva 2014 1at Quarter Revenue

AREVA's operations generated consolidated revenue of 1.781 billion euros in the first quarter of 2014, a decrease of 18.1% (-17.3 % like for like) compared with the same period in 2013.

Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance

Mallinckrodt plc a leading global specialty pharmaceutical company, today reported results for the second quarter of fiscal 2014, which ended March 28, 2014.

FDA, EMA Grant Orphan Drug Status to Gallium-68 Dotatate Radiopharmaceutical

Advanced Accelerator Applications (AAA), a growing international player in molecular nuclear medicine, announced they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 Dotatate.

Update on Mo-99 Availability

The ongoing Molybdenum-99 (Mo-99) supply challenges faced by the nuclear medicine industry remain in effect. Based on currently available resources and projections for Mo-99 supply, generator standing orders should be met throughout March.

NRU Reactor Scheduled for Maintenance in April, Disrupting Mo-99 Supply

The NRU reactor is scheduled to enter into its maintenance April 13, and anticipates restarting May 13, with resumption of their Mo-99 supply on May 17.

AREVA Group Chooses Caen (France) as the Location for Its Second Lead-212 Production Facility

Luc Oursel, President of AREVA, announced the selection of the Caen la Mer urban community (Calvados, France) as the location for its second lead-212 production facility.

Priority Review Given for the Expanded Use of Lymphoseek (Technetium-99m Tilmanocept) Injection

Navidea Biopharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek (technetium 99m tilmanocept) Injection.